News & Views
GHIT Grant to Advance Neglected Disease Drug Discovery
Apr 30 2020
The University of Liverpool’s Department of Chemistry and the Liverpool School of Tropical Medicine (LSTM), together with Japanese pharmaceutical company Eisai, have been awarded a Global Health Innovative Technology (GHIT) grant which will fund the development of a new drug to target the neglected tropical diseases lymphatic filariasis (LF) and onchocerciasis, both debilitating infections affecting more than 150 million people globally.
The £3,250,000 funding for this new phase will support a series of Phase I human clinical trials, which will assess the safety of the drug in humans.
LSTM’s Deputy Director and project lead, Professor Steve Ward said “We are extremely pleased and proud to be able to continue this unique partnership between LSTM, the University of Liverpool and Eisai. Our approach of killing the parasitic worm by targeting the essential bacteria within the worm is totally unique and one that offers many advantages over drugs that target worms directly.”
Proof-of-concept clinical trials have already shown that this alternative approach works and can reduce elimination timeframes significantly from decades to years. The drug candidate also has the potential to be used in the whole population, including children and pregnant women.
AWZ1066S, provides a unique opportunity to make a large contribution to communities affected by these diseases.
This novel molecule was developed from a screening hit by several rounds of chemistry optimisation at the University’s Department of Chemistry.
Liverpool Chemist, Professor Paul O’Neill, said “ Our optimisations from a hit to preclinical candidate were achieved in under three years which underlines the success of the medicinal chemistry approaches used in this project.”
Dr David Hong, development team, added: “Receiving the financial support (award) from GHIT to enable the progression to human clinical trials is an important milestone in filariasis drug discovery.”
The GHIT Fund facilitates and funds global partnerships for the discovery and development of new health technologies, including drugs, vaccines and diagnostics, for infectious and neglected tropical diseases prevalent in developing countries.
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark